Suppr超能文献

与良性前列腺增生相比,人类前列腺癌中肌酸激酶的降低。

Decrease in creatine kinase in human prostatic carcinoma compared to benign prostatic hyperplasia.

作者信息

Pretlow T G, Whitehurst G B, Pretlow T P, Hunt R S, Jacobs J M, McKenzie D R, McDaniel H G, Hall L M, Bradley E L

出版信息

Cancer Res. 1982 Nov;42(11):4842-8.

PMID:6181869
Abstract

Many previous studies have shown that a proportion of patients with carcinoma of the prostate have increased activity of the creatine kinase (E.C. 2.7.3.2) isoenzyme designated BB in sera from their peripheral blood. We have analyzed tissues from prostatic hyperplasia of 22 patients and from prostatic carcinoma of 23 additional patients. Prostatic carcinomas contain less (p less than 0.001) creatine kinase activity (units/g) than do prostates with benign prostatic hyperplasia. The facts that (a) histochemical studies that we performed confirmed the observation reported previously by others that creatine kinase activity is found primarily in the epithelial elements of hyperplastic prostates and prostatic carcinomas, (b) the carcinomas that we examined had, on the average, a somewhat larger epithelial component than the hyperplastic prostates that we examined, and (c) prostate cancer was found to contain less creatine kinase activity than hyperplastic prostates suggest that the epithelial cells in prostate cancers contain less creatine kinase activity per cell than do those from hyperplastic prostates. The BB form of creatine kinase accounts for 98% of the activity in prostatic carcinoma and in prostates without cancer. Creatine kinase has been discussed as a possible marker for prostatic carcinoma, and we had hoped that it might be useful for the assay of tumor burden. Our data suggest that, if creatine kinase is to be useful in the monitoring of tumor burden, it will be useful only in the contexts of particular patients studied longitudinally since the creatine kinase activity varies enormously among different prostatic carcinomas.

摘要

许多先前的研究表明,一部分前列腺癌患者外周血血清中肌酸激酶(E.C. 2.7.3.2)同工酶BB的活性有所增加。我们分析了22例前列腺增生患者和另外23例前列腺癌患者的组织。前列腺癌组织中的肌酸激酶活性(单位/克)低于良性前列腺增生的前列腺组织(p<0.001)。以下事实表明:(a)我们进行的组织化学研究证实了其他人先前报告的观察结果,即肌酸激酶活性主要存在于增生性前列腺和前列腺癌的上皮细胞中;(b)我们检查的癌组织平均而言,其上皮成分比我们检查的增生性前列腺组织略大;(c)前列腺癌的肌酸激酶活性低于增生性前列腺组织,这表明前列腺癌上皮细胞中每个细胞的肌酸激酶活性低于增生性前列腺组织中的上皮细胞。肌酸激酶的BB形式在前列腺癌和非癌前列腺组织的活性中占98%。肌酸激酶已被讨论作为前列腺癌的一种可能标志物,我们曾希望它可能对肿瘤负荷的检测有用。我们的数据表明,如果肌酸激酶要用于监测肿瘤负荷,它仅在对特定患者进行纵向研究的情况下才有用,因为不同前列腺癌之间的肌酸激酶活性差异极大。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验